Clinical Trial Update: Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ST-503, a safety and tolerability study in Phase 1/2 for refractory pain due to peripheral neuropathy, including small fiber predomina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain
• Peripheral Neuropathy
• Small Fiber Neuropathy

Drugs mentioned

• ST-503

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Chronic Neuropathic Pain | Phase 1, Phase 2 | Status: RECRUITING